Identification

Generic Name
Sitimagene ceradenovec
DrugBank Accession Number
DB04907
Background

Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.

Type
Biotech
Groups
Investigational
Biologic Classification
Gene Therapies
Other gene therapies
Synonyms
  • Sitimagene ceradenovec
External IDs
  • EG009

Pharmacology

Indication

Intended for the treatment of brain cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

EG009 is comprised of a gene encased in a virus vector. Vectors transfer their gene payload into target cells, a process known as transfection, which use this new genetic material as a blueprint for the production of new beneficial proteins. EG009 uses a well-established adenoviral vector (Ad5) to introduce the gene that causes cells to express a protein called thymidine kinase (TK). Following the standard surgery to remove the solid tumour mass, EG009 is injected through the wall of the cavity left behind by the surgical removal of the solid tumour, into the surrounding healthy brain tissue. In the following days, the healthy cells in the wall of the cavity express TK. Five days after surgery, the drug ganciclovir (GCV) is given to the patient as part of the overall EG009 treatment regimen. Neither TK nor GCV is individually active but they react together to produce a substance which destroys cells when they try to divide. Since cell division is a key characteristic of cancer and the normal brain cells are not dividing, cells that try to divide to form a new tumour around the site of the removal of the original tumour are targeted for destruction by the EG009 treatment. EG009 thus works by harnessing healthy cells to produce the substances necessary to destroy newly growing cancer cells.

Mechanism of action

EG009 works by delivering a gene into the healthy brain cells remaining after the tumour has been removed. These then produce an enzyme that kills the cells trying to divide, preventing a recurrence of a tumour.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Cinchocaine.
CocaineThe risk or severity of methemoglobinemia can be increased when Sitimagene ceradenovec is combined with Cocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Cerepro

Categories

ATC Codes
L01XX37 — Sitimagene ceradenovec
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Not Available
CAS number
898830-54-1

References

General References
Not Available
PubChem Substance
347909845

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at October 21, 2007 22:23 / Updated at January 14, 2023 19:03